Our Nanospot.ai diagnostic test platform is based on the classic hemagglutination (red blood cell clumping) test. Hemagglutination is a well established and highly sensitive diagnostic test, which is commonly used for blood typing, but can also be used for antibody testing, in particular in point-of-care settings. One drawback of current hemagglutination tests is the subjective readout by the human eye, which can lead to incorrect test interpretation. Moreover, current tests lack the ability to quantify test results.
To overcome these limitations, we developed an AI-based approach, which uses cell phone images of the hemagglutination reaction for objective test interpretation. Moreover, we included internal standards into each test card, which extends capabilities to quantitative test interpretation right at the point-of-care.
The NanoSpot.ai method is based on a recombinant, bi-functional protein containing a high-affinity binding site for red blood cells and a protein that serves as a target (antigen) for the antibodies to be detected. Upon mixing with venous or finger-stick blood, the recombinant protein will bind to red blood cells (RBC). If antibodies (e.g. against SARS-CoV2) are present, they will bind to the bi-functional protein, resulting in crosslinking and visually apparent hemagglutination (clumping) of the RBC. In the absence of antibodies, the RBC will not agglutinate.
The Agglutination Reaction
NanoSpot.ai reagent added to whole blood
NanoSpot.ai reagent binds to red blood cells
Antibodies present in whole blood bind to antigen present in the NanoSpot.ai reagents and cause agglutination (clumping) of red blood cells
Our APP for AI-based Diagnostic Testing
While a positive (agglutination) or negative (no agglutination) result can be determined from the card alone the NanoSpot.ai app is required for AI-based analysis and precise quantification of the test result. The user-friendly app can be downloaded from the app store. The app provides data entry, scanning, automatic data upload, and result return. The app also provides instructions, video tutorials and frequently asked questions to assist the user in running a successful test.
The NanoSpot.ai Advantage
Learn More About Our Products
Our flagship product is the NanoSpot.ai Sars-CoV-2 antibody test. The NanoSpot.ai testing platform can easily expanded to other serology tests and beyond. Several additional tests from blood grouping to infectious diseases are currently in the pipeline and are expected to be released soon.
Blood Grouping Test
The NanoSpot.ai rapid ABO/RhDblood grouping kit allows safe, easy and fast determination of your blood type and Rh factor on site and at home.
The NanoSpot.ai SARS-CoV-2 Total Antibody Test has been CE Marked.
The NanoSpot.ai SARS-CoV-2 Total Antibody Test has not been FDA cleared, approved, or authorized under an emergency use authorization.
The NanoSpot.ai Website may depict certain of our future planned care offerings which are subject to completion of development and may require regulatory authorization, clearance, or approval before they can be commercialized.